Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Oral arginine emerges as potential adjuvant for vaso-occlusive crisis management
Key clinical point: Oral arginine could be a promising adjuvant therapy for vaso-occlusive crisis management in patients with sickle cell disease.
Major finding: Plasma arginine levels increased by 125% vs. 29% in the arginine vs. placebo arms, respectively, and crisis resolution was achieved by 25% of patients in 72 vs. 120 hours in the arms, respectively.
Study details: Randomized, placebo-controlled, phase 2 trial of 68 Nigerian children.
Disclosures: Dr. Onalo reported having no disclosures.
Citation:
Onalo R et al. ASH 2019, Abstract 613.